Xin Zhou

Dr. Xin Zhou

Jiangsu Province Hospital, Nanjing, Jiangsu, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Gene
Verified
Journal Article
Closed access
HZHuo Zhang
Huo Zhang
MZMingxia Zhu
Mingxia Zhu
XSXia Shan
Xia Shan
XZXin Zhou
Xin Zhou
TWTongshan Wang
Tongshan Wang
WZWei Zhu
Wei Zhu

1 October 2018 in Gene
Verified
Journal Article
Closed access
XZXin Zhou
Xin Zhou
ZLZipeng Lu
Zipeng Lu
TWTongshan Wang
Tongshan Wang
ZHZebo Huang
Zebo Huang
WZWei Zhu
Wei Zhu
YMYi Miao
Yi Miao

11 December 2019 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
GMGe Ma
Ge Ma
GSGuoxin Song
Guoxin Song
XZXuan Zou
Xuan Zou
XSXia Shan
Xia Shan
QLQingxie Liu
Qingxie Liu
WZWei Zhu
Wei Zhu
OBJECTIVE: To determine the utility of plasma microRNAs (miRNAs) as biomarkers in cervical cancer (CC). METHODS: Some studies were conducted about the specific expression of plasma miRNAs in the diagnosis of CC. Plasma samples of 97 CC patients and 8

2 February 2024 in Aging
Verified
Journal Article
Open access
PDF file
MZMingxia Zhu
Mingxia Zhu
XWXiaping Wang
Xiaping Wang
QZQing Zhang
Qing Zhang
CXChen Xie
Chen Xie
TWTongshan Wang
Tongshan Wang
XZXin Zhou
Xin Zhou
Targeting Protein for Xenopus Kinesin Like Protein 2 (TPX2) serves as a microtubule associated protein for the regulation of spindle assembly and tumorigenesis. We aim to investigate the prognostic and immunological role of TPX2 in pan-cancer. TCGA database, Tumor Immune Single-cell Hub (TISCH), and Human Protein Atlas (HPA) were retrieved to evaluate the expression pattern of TPX2 as well as its diagnostic and prognostic value in solid tumors. Genomic alterations of TPX2 were assessed with cBioPortal database. In vitro experiments in lung adenocarcinoma (LUAD) were performed to confirm the potential role of TPX2. Overexpression of TPX2 was found in 22 types of cancers, and was positively related with copy number variations (CNV) and negative with methylation. Up-regulated TPX2 could predict worse outcomes in the majority of cancers. Single-cell analysis revealed that TPX2 was mainly distributed in malignant cells (especially in glioma) and proliferating T cells. Genomic alteration of TPX2 was common in different types of tumors, while with prognostic value in two types of cancers. Additionally, significant correlations were found between TPX2 expression and tumor microenvironment (including stromal cells and immune cells) as well as immune related genes across cancer types. Drug sensitivity analysis revealed that TPX2 could predict response to chemotherapy and immunotherapy. Functional analyses demonstrated close relationship of TPX2 with immune function and malignant phenotypes. Finally, it was confirmed that knockdown of TPX2 could reduce proliferation and migration ability of LUAD cells. In summary, TPX2 could serve as a diagnostic and prognostic biomarker and a potential immunotherapy marker.

1 April 2019 in Gene
Verified
Journal Article
Closed access
ZWZhiyan Wang
Zhiyan Wang
JLJinru Lv
Jinru Lv
XZXuan Zou
Xuan Zou
ZHZebo Huang
Zebo Huang
HZHuo Zhang
Huo Zhang
WZWei Zhu
Wei Zhu

27 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YSYue Sun
Yue Sun
LLLi Liu
Li Liu
YFYuanyuan Fu
Yuanyuan Fu
YLYaoyao Liu
Yaoyao Liu
XGXuan Gao
Xuan Gao
XZXin Zhou
Xin Zhou
Background: Little is known on how metabolic reprogramming potentially prompts transition of activated and resting CD4+ memory T cells infiltration in tumor microenvironment of gastric cancer (GC). The study aimed to evaluate their interactions and develop a risk model for predicting prognosis in GC.Methods: Expression profiles were obtained from TCGA and GEO databases. An immunotherapeutic IMvigor210 cohort was also enrolled. CIBERSORT algorithm was used to evaluate the infiltration of immune cells. The ssGSEA method was performed to assess levels of 114 metabolism pathways. Prognosis and correlation analysis were conducted to identify metabolism pathways and genes correlated with activated CD4+ memory T cells ratio (AR) and prognosis. An AR-related metabolism gene (ARMG) risk model was constructed and validated in different cohorts. Flow cytometry was applied to validate the effect of all-trans retinoic acid (ATRA) on CD4+ memory T cells.Results: Since significantly inverse prognostic value and negative correlation of resting and activated CD4+ memory T cells, high AR level was associated with favorable overall survival (OS) in GC. Meanwhile, 15 metabolism pathways including retinoic acid metabolism pathway were significantly correlated with AR and prognosis. The ARMG risk model could classify GC patients with different outcomes, treatment responses, genomic and immune landscape. The prognostic value of the model was also confirmed in the additional validation, immunotherapy and pan-cancer cohorts. Functional analyses revealed that the ARMG model was positively correlated with pro-tumorigenic pathways. In vitro experiments showed that ATRA could inhibit levels of activated CD4+ memory T cells and AR.Conclusion: Our study showed that metabolic reprogramming including retinoic acid metabolism could contribute to transition of activated and resting CD4+ memory T cells, and affect prognosis of GC patients. The ARMG risk model could serve as a new tool for GC patients by accurately predicting prognosis and response to treatment.